High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer

Cancer Research

Volumn 61, Issue 14, 2001, Pages 5407-5414

  Foekens, John A ^a   Peters, Harry A ^a   Grebenchtchikov, Nicolai ^b   Look, Maxime P ^a   Meijer van Gelder, Marion E ^a   Geurts Moespot, Anneke ^b   Van der Kwast, Theo H ^a   Sweep, C G J ^a,b   Klijn, Jan G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOKINES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035878753     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. What is the evidence that tumors are angiogenesis dependent?
2. Tumor angiogenesis: Therapeutic implications
3. Clinical applications of research on angiogenesis
4. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
5. Angiogenesis in cancer and other diseases
6. The implications of angiogenesis for the biology and therapy of cancer metastasis
7. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
8. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
9. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer
10. Association of angiogenesis in lymph node metastasis with outcome of breast cancer
11. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
12. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing
13. Regulation of angiogenesis via vascular endothelial growth factor receptors
14. Vascular endothelial growth factor (VEGF) and its receptors
15. Tumor induction of VEGF promoter activity in stromal cells
16. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
17. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
18. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients
19. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
20. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
21. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
22. Expression of the angiogeneic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
23. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
24. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
25. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
26. Breast cancer angiogenesis and tamoxifen resistance
27. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients
28. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
29. Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
30. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
31. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors α and β
32. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor
33. Progestin regulation of vascular endothelial growth factor in human breast cancer cells
34. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
35. Estrogen regulates vascular endothelial growth/permeability factor expression in 7, 12-dimethyl-benz(a)anthracene-induced rat mammary tumors
36. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study
37. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer
38. Revision of the standards for the assessment of hormone receptors in human breast cancer: Report of the second E. O. R. T. C
39. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols
40. EORTC receptor and biomarker study group report: A sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts
41. Non-parametric estimation from incomplete observations
42. Clinical applications of angiogenic growth factors
43. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool
44. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis
45. Changes in vascularization in human breast cancer xenografts responding to antiestrogen therapy
46. Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
47. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
48. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma
49. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors
50. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
51. VEGF expression by epithelial and stromal cell compartments
52. Production of VEGF and expression of the VEGF receptors Flt-I and KDR in primary cultures of epithelial and stromal cells derived from breast tumours
53. Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas
54. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
55. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
56. TGF β-1 regulation of VEGF production by breast cancer cells
57. Vascular endothelial growth factor and the regulation of angiogenesis
58. Growth factors in breast cancer
59. Tamoxifen induces TGF-β 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro
60. 1 in human breast cancer in vivo following tamoxifen treatment
61. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor β-1
62. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
63. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
64. Regulation of vascular endothelial growth factor expression in human carcinoma cells by cell density
65. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer
66. Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy
67. An immunohistochemical study of π class glutathione S-transferase expression in normal human tissue